Cellectis ( Cellectis )

Cellectis

Cellectis's picture

Cellectis a biopharmaceutical company focused on developing immunotherapies based on genome-edited CAR T-cells (UCARTs).[1] Cellectis was founded in 1999 and designs novel products including immune therapies for cancer and enzymes which can add DNA at targeted places in genomes.

Cellectis press release, blog etc

02/12/2018 - 23:55 Two Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells
12/12/2017 - 19:16 Preliminary Data from Servier and Pfizers UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials
12/03/2017 - 21:28 Cellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development
12/03/2017 - 20:12 Cellectis Appoints Immuno-Oncology Leader Stephane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer
11/20/2017 - 15:31 Cellectis Demonstrates Fine and Predictable Tuning of TALEN Gene Editing Targeting to Improve T-cell Adoptive Immunotherapy
11/06/2017 - 17:36 FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN
11/01/2017 - 16:52 Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting
09/04/2017 - 11:08 Cellectis to Participate in Upcoming Investor Conferences
09/04/2017 - 09:17 Cellectis Reports Clinical Hold of UCART123 Studies
08/17/2017 - 14:51 Cellectis UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer Center
07/25/2017 - 11:30 Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering
07/24/2017 - 15:00 Cellectis Granted Patent for CRISPR Use in T-Cells
07/19/2017 - 16:34 Calyxt Announces Pricing of $56.0 Million Initial Public Offering
07/10/2017 - 03:33 Calyxt Announces Proposed Initial Public Offering of $100.0 Million
06/26/2017 - 20:04 First in Human Administration of UCART123 in Cellectis AML Phase I Clinical Trial at Weill Cornell Medicine, NewYork-Presbyterian Hospital
06/25/2017 - 20:10 Annual General Meeting of June 26, 2017
06/25/2017 - 19:49 Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2017
06/22/2017 - 19:58 Calyxt Files Registration Statement for Proposed Initial Public Offering